간질 치료제 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Epilepsy Treatment Drugs Market reached USD 8.6 billion in 2024 and is projected to expand at a CAGR of 5.1% from 2025 to 2034. The growth is driven by an increasing prevalence of epilepsy, advancements in pharmaceutical research, and rising investments from government and private organizations. The rising number of epilepsy cases worldwide is fueling demand for effective medications, while breakthroughs in drug development are leading to the introduction of innovative treatment options with enhanced efficacy and fewer side effects. Ongoing research and development initiatives are paving the way for next-generation epilepsy medications that offer improved patient outcomes and greater therapeutic benefits.

Pharmaceutical companies are investing heavily in clinical trials and regulatory fast-tracking to bring advanced anti-epileptic drugs to market faster. The growing elderly population, which is more susceptible to neurological disorders, is further contributing to the demand for epilepsy medications. Additionally, increased awareness campaigns, improved healthcare infrastructure, and better access to medications are strengthening market expansion. The introduction of precision medicine and personalized treatment approaches is also playing a pivotal role in reshaping the epilepsy treatment landscape. As drug manufacturers continue prioritizing safety and efficacy, the market is witnessing an influx of new formulations with optimized dosing and minimal adverse effects.

The market is segmented based on drug class into first-generation, second-generation, and third-generation drugs. Second-generation drugs dominated in 2024, accounting for 49% of the total market share, and are anticipated to grow at a CAGR of 5.2% through 2034. Their widespread adoption is primarily attributed to better patient compliance, lower risk of drug interactions, and fewer side effects compared to first-generation alternatives. Regulatory bodies are increasingly expediting approvals for these medications due to their effectiveness in treating multiple neurological disorders beyond epilepsy. As pharmaceutical companies continue to enhance their portfolios, the demand for second-generation epilepsy drugs is expected to rise significantly.

The market is also categorized by drug type into branded and generic epilepsy treatment medications. In 2024, the branded segment led the market, capturing 59.1% of total revenue, and is projected to reach USD 8.1 billion by 2034. Pharmaceutical firms are focusing on the development of branded epilepsy drugs with enhanced safety profiles and improved therapeutic performance, fueling demand for premium treatment solutions. Patients and healthcare providers increasingly prefer branded medications due to their reliability, effectiveness, and reduced risk of side effects. With the ongoing shift toward next-generation branded therapies, the market is poised for sustained growth.

The United States remains a key contributor to epilepsy treatment drug sales, with the market projected to generate USD 4.6 billion by 2034. The rising number of epilepsy cases is driving strong demand for anti-epileptic medications, while government initiatives and research funding are accelerating drug development. Federal programs aimed at improving treatment accessibility and advancements in therapeutic strategies are further strengthening market expansion. As pharmaceutical companies continue innovating and securing regulatory approvals, the U.S. market is expected to maintain its dominant position in the global epilepsy treatment drugs industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of epilepsy
    • 3.2.1.2 Increasing investments in research and development activities
    • 3.2.1.3 Increasing demand for novel treatment for epilepsy
    • 3.2.1.4 Growing awareness and early diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects associated with the antiepileptic drugs
    • 3.2.2.2 Patent expiration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 First-generation
• 5.3 Second-generation
• 5.4 Third-generation

Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Generics

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Nasal
• 7.4 Injectable
• 7.5 Rectal

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult

Chapter 9 Market Estimates and Forecast, By Seizure Type, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Focal seizure
• 9.3 Generalized seizure
• 9.4 Combined seizure

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 Bausch Health Companies
• 12.2 Dr. Reddy's Laboratories
• 12.3 Eisai
• 12.4 GlaxoSmithKline
• 12.5 Jazz Pharmaceuticals
• 12.6 Neurelis
• 12.7 Novartis
• 12.8 Novel Laboratories
• 12.9 Pfizer
• 12.10 Sanofi
• 12.11 SK Biopharmaceuticals
• 12.12 SUMITOMO PHARMA
• 12.13 Sun Pharmaceutical Industries
• 12.14 UCB Pharma